{"id":"nvk-002-concentration-1","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Hyperthyroidism"}]},"_chembl":{"chemblId":"CHEMBL4303334","moleculeType":"Small molecule","molecularWeight":"612.64"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the PD-1 receptor, NVK-002 Concentration 1 prevents the interaction with its ligand, PD-L1, thereby activating T cells and enhancing anti-tumor immune response.","oneSentence":"NVK-002 Concentration 1 is a drug that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:30.795Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT03350620","phase":"PHASE3","title":"CHAMP: Study of NVK-002 in Children With Myopia","status":"COMPLETED","sponsor":"Vyluma, Inc.","startDate":"2017-11-20","conditions":"Myopia","enrollment":670}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6878,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NVK-002 Conc 1"],"phase":"phase_3","status":"active","brandName":"NVK-002 Concentration 1","genericName":"NVK-002 Concentration 1","companyName":"Vyluma, Inc.","companyId":"vyluma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NVK-002 Concentration 1 is a drug that targets the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}